CEO Executive AssistantBiotech companies live and die by the quality and speed of their science. For a biotech CEO, this creates a persistent tension: the more technically fluent they are, the more tempted they are to stay embedded in research decisions. But a CEO who is running experiments in their head while sitting in investor meetings is not fully present in either place.
A delegation matrix for biotech CEO research operations solves this tension by creating a clear map of who owns what across the scientific organization. It gives the CEO a structured way to stay informed without being in the operational center of every research decision.
Why Biotech CEOs Struggle to Delegate Research
Biotech is founded on deep science, and many biotech CEOs are scientists first. They may have discovered the core technology, published the foundational papers, or personally recruited the lead investigators. Their scientific credibility is often part of what attracted early investors and built the initial team.
This scientific identity creates delegation resistance. When the CEO has a strong opinion about assay design, target selection, or data interpretation, stepping back feels like giving up something fundamental to who they are.
But as an organization scales from a lab bench to a clinical-stage company, the CEO’s scientific involvement must evolve. The cost of keeping the CEO in research operations grows with every hire, every program, and every investor dollar. The research organization needs leaders who are present, empowered, and accountable, not leaders who are waiting for the CEO to weigh in before moving.
What a Delegation Matrix Is and Why It Works
A delegation matrix is a structured document that maps specific decision types to specific roles, with clarity about when escalation or approval is needed. In research operations, it answers: Who decides what? Who gets informed? Who has veto authority?
Delegation matrices work in biotech because research decisions have natural categories that can be assigned to domain experts without requiring CEO judgment on each one. The CEO’s role shifts from decider to reviewer, from operator to strategist.
The matrix does not mean the CEO is out of the loop. It means the CEO is informed through a structured reporting system rather than ad hoc involvement.
Building the Delegation Matrix: Research Operations Categories
Program Strategy and Portfolio Decisions
These are decisions about which research programs to advance, deprioritize, or kill. They are among the highest-stakes decisions a biotech makes, and they belong at the CEO level, in collaboration with the Chief Scientific Officer (CSO) and often the Board.
Owner: CEO with CSO input Frequency: Quarterly portfolio reviews, plus milestone-triggered reviews Supporting input from: Program leads, translational team, finance (for resource modeling)
The CEO should not be making these decisions in real time as individual experiments come in. The right cadence is a structured portfolio review where aggregated data and scientific judgment inform a strategic decision.
Target and Mechanism Research
Decisions about which biological targets to pursue, which mechanisms of action to validate, and which hypotheses to test are scientific questions that belong to the CSO and program leads.
Owner: CSO and Research Program Leads CEO involvement: Informed via monthly science update; engaged only when a target decision has portfolio or partnership implications Escalation trigger: Target failure that impacts the primary pipeline program
The CEO does not need to approve each new hypothesis. They need to know the overall research direction and be notified when a major direction changes.
Experimental Design and Protocol Decisions
Individual experimental design, assay development, and protocol decisions are the domain of Principal Investigators and Research Scientists. These decisions happen daily across the research organization. CEO involvement would be both impractical and counterproductive.
Owner: Principal Investigators and Research Scientists Oversight: CSO reviews experimental outputs at program-level meetings CEO involvement: None at the individual experiment level
The CEO’s confidence in this delegation comes from having hired and trusted a strong CSO who is actively engaged with the science.
Data Review and Interpretation
When experimental data comes in, who interprets it? Who decides whether results are compelling enough to advance a program?
Owner: Scientific Advisory Board (for periodic external review), CSO, and Program Leads for routine data review CEO involvement: Briefed on data that changes program trajectory; presented with data at portfolio reviews Escalation trigger: Data that triggers a major go/no-go decision
According to Forbes research on biotech leadership, the most effective biotech CEOs describe their role in research as “asking the right questions” rather than providing the right answers. This framing helps calibrate the CEO’s involvement: engage to understand and challenge, not to direct.
Research Hiring and Team Building
Research headcount decisions have strategic and financial implications, but the day-to-day hiring process should not require CEO involvement for most positions.
Owner: CSO for all research hires; CEO approval required for VP-level and above Standard process: Hiring manager defines the role, recruiter sources candidates, interview panel scores, CSO approves offer CEO involvement: Interviews VP-level candidates and above; is briefed on research team growth quarterly
Budget and Resource Allocation Within Research
Research budgets are set annually through a process the CEO leads. Within that approved budget, resource allocation decisions should be owned by the CSO.
Owner: CSO for in-year resource allocation decisions within approved budget CEO involvement: Annual budget approval; notified for any over-budget request above a defined threshold (example: $500,000)
Giving the CSO budget authority within guardrails is one of the highest-value delegation moves a biotech CEO can make. It speeds decision-making significantly.
External Research Collaborations and Academic Partnerships
Partnerships with academic institutions, research hospitals, or government agencies often involve contracts, IP considerations, and relationship management. These require cross-functional input.
Owner: CSO for scientific scope; General Counsel or BD Lead for contract and IP terms; CEO for strategic partnerships CEO involvement: Reviews and approves strategic partnerships; informed of smaller academic collaborations Escalation trigger: Any collaboration involving equity, milestone payments, or exclusive IP licensing
Creating the Living Matrix Document
Once you have mapped decisions to owners, document the matrix in a format that your leadership team can reference and update. A simple spreadsheet works well with four columns:
- Decision Category (specific and named)
- Primary Owner (role title, not person name)
- CEO Involvement Level (None / Informed / Consulted / Approves)
- Escalation Trigger (the condition under which this changes)
Review and update the matrix at each annual planning cycle and whenever the organization makes a significant structural change, such as adding a new research program, promoting a senior scientist, or bringing in a new CSO.
Supporting the Delegation Matrix with the Right Reporting Structure
A matrix without reporting is just a document. To make delegation real, build a reporting rhythm that keeps the CEO connected to research progress without requiring operational involvement.
Weekly Science Briefing (15-30 minutes)
The CSO gives the CEO a brief weekly update: what are the most important things that happened in research this week? What decisions are coming up in the next two weeks? What does the CEO need to know?
This meeting replaces the CEO’s need to attend research team meetings or read every lab report. The CSO acts as the CEO’s scientific intelligence officer.
Monthly Research All-Hands
A monthly research update meeting open to the scientific organization gives the CEO visibility into the breadth of what the team is working on, without requiring them to be in program meetings. The CEO attends, asks strategic questions, and thanks the team. The scientific detail is owned by program leads.
Quarterly Portfolio Review
The formal portfolio review is the CEO’s primary strategic engagement with research. Each program lead presents: current status, key data from the quarter, upcoming milestones, resource needs, and risks. The CEO and CSO make go/no-go and priority decisions based on the aggregated picture.
This meeting is high-value, high-signal, and infrequent enough to respect the CEO’s calendar.
Delegating Research Operations: The Infrastructure Layer
Research operations includes more than the science itself. Procurement, lab management, equipment maintenance, safety protocols, and data management are operational functions that should be fully delegated.
A Head of Research Operations (or Lab Operations Manager) should own:
- Lab equipment procurement and maintenance schedules
- Scientific computing and informatics infrastructure
- Biosafety and environmental health and safety compliance
- Reagent and consumable procurement and inventory management
- Vendor relationships for research services and CRO partnerships
These functions are critical to research productivity but carry no strategic ambiguity. A capable operations leader can own them completely. For related frameworks on how scientific CEOs delegate R&D work, see our guide on how biotech CEOs delegate R&D.
Common Delegation Mistakes in Biotech Research
Delegating the Role but Not the Authority
Many biotech CEOs hire a CSO and then continue to be pulled into research decisions because the organization does not actually defer to the CSO. This is especially common when the CEO is the scientific founder and team members still default to them for direction.
Fix this by explicitly and publicly transferring scientific authority to the CSO. In all-hands meetings, in one-on-ones with program leads, and in your own behavioral choices, reinforce that the CSO is the scientific decision-maker.
Over-Escalating Data to the CEO
Research teams sometimes escalate every interesting data point to the CEO, either because they are excited and want to share, or because they are uncertain about what the data means for program direction. This creates noise in the CEO’s information environment.
Define escalation criteria clearly: share data with the CEO when it changes program trajectory, not when it is simply interesting.
Removing the CEO from Investor-Facing Science
While the CEO should step back from research operations, they should remain closely connected to investor-facing scientific narrative. The CEO who cannot speak fluently about their company’s science in a board meeting or investor presentation has delegated too far.
The CEO should spend enough time with the CSO and program leads to maintain a sophisticated, high-level understanding of the science even while delegating the execution.
For additional context on delegating across pharma and biotech clinical programs, our article on pharma CEO clinical delegation strategies covers how these frameworks extend into the clinic.
Aligning the Matrix with Company Stage
The right delegation matrix for a seed-stage biotech with five scientists looks different from the matrix for a series B company with 60 researchers and three programs.
Early stage (pre-series A): The CEO is naturally more involved. With a small team, the CEO may function as a de facto CSO. The matrix should still exist, even informally, to create habit. Define what you are deciding vs. what your lead scientist decides.
Series A to B: This is when the delegation matrix becomes critical. The scientific team is large enough that CEO involvement in individual decisions creates delays and disempowerment. Hire a CSO if you have not already. Formalize the matrix.
Clinical stage and beyond: Research operations and clinical development separate into distinct functions. The research delegation matrix may now cover discovery and early preclinical work only, with a separate framework for clinical operations.
Conclusion
A delegation matrix for biotech CEO research operations is not a bureaucratic formality. It is the structure that allows a scientific organization to move at the pace the competitive landscape demands. When CEOs build clear ownership maps, invest in a strong CSO, create reporting rhythms that keep them informed without pulling them into execution, and explicitly transfer authority to domain experts, they unlock research velocity that CEO-centered organizations cannot match.
The best biotech CEOs are scientifically engaged, strategically present, and operationally delegated. The matrix makes all three of those things possible at the same time.
Related Reading
For further context, explore Delegation Matrix for Arts Nonprofit CEOs and Delegation Matrix for Automotive CEO: Capital Projects.